ONECHAIN IMMUNOTHERAPEUTICS

onechain-immunotherapeutics-logo

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

#SimilarOrganizations #People #Financial #Website #More

ONECHAIN IMMUNOTHERAPEUTICS

Social Links:

Industry:
Biotechnology Life Science

Founded:
2020-01-01

Address:
Barcelona, Catalonia, Spain

Country:
Spain

Website Url:
http://www.onechaintx.com

Total Employee:
1+

Status:
Active

Total Funding:
3.05 M EUR

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Global Site Tag Euro


Similar Organizations

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.

immpact-bio-logo

ImmPACT Bio

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

Current Employees Featured

not_available_image

Pablo Menéndez
Pablo Menéndez President, Founder and CSO @ OneChain Immunotherapeutics
President, Founder and CSO

not_available_image

Jorge Alemany Herrera
Jorge Alemany Herrera CEO @ OneChain Immunotherapeutics
CEO
2020-07-01

Founder


not_available_image

Pablo Menéndez

Investors List

invivo-capital-partners_image

Invivo Capital Partners

Invivo Capital Partners investment in Seed Round - OneChain Immunotherapeutics

josep-carreras-leukaemia-research-institute_image

Josep Carreras Leukaemia Research Institute

Josep Carreras Leukaemia Research Institute investment in Seed Round - OneChain Immunotherapeutics

catalan-institution-for-research-and-advanced-studies_image

Catalan Institution for Research and Advanced Studies

Catalan Institution for Research and Advanced Studies investment in Seed Round - OneChain Immunotherapeutics

Official Site Inspections

http://www.onechaintx.com

  • Host name: shx814.guebs.net
  • IP address: 185.23.70.117
  • Location: Spain
  • Latitude: 40.4172
  • Longitude: -3.684
  • Timezone: Europe/Madrid

Loading ...

More informations about "OneChain Immunotherapeutics"

Board of directors - Onechaintx

Pablo Menéndez Founder and CSO. Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology …See details»

Team - OneChain

Cristina also has more than 15 years of experience in the Financial Sector, were she worked as Senior Management Executive Assistant and as Deputy Director and Account Manager of bank office. Cristina joined OneChain …See details»

OneChain Immunotherapeutics - Crunchbase Company Profile

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against …See details»

OneChain Immunotherapeutics SL - Drug pipelines, Patents, …

Sign Up for Free. Last update 01 Nov 2024See details»

OneChain Immunotherapeutics Overview | SignalHire Company …

OneChain Immunotherapeutics is a spin-off Company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop CAR-T candidates against different …See details»

OneChain - Wiki - Golden

OneChain is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop immunotherapies against hematological neoplasms using CAR-T …See details»

OneChain Immunotherapeutics - Overview, News & Similar

View OneChain Immunotherapeutics (www.onechaintx.com) location in Spain , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»

OneChain Immunotherapeutics Company Information - Funding, …

OneChain Immunotherapeutics, based in Barcelona, specializes in developing CAR-T therapies for leukemia. This niche focus distinguishes them from traditional treatments like …See details»

:site_name - onechaintx.com

OC-1 CART CD1a Immunotherapy. T-ALL comprises 10–15% of all acute leukemias diagnosed in children and 20–25% in adults, with a median diagnostic age of 9 years.See details»

Onechain Immunotherapeutics - Company Profile - Tracxn

Nov 13, 2024 Onechain Immunotherapeutics ranks 188th among 311 active competitors. 122 of its competitors are funded while 76 have exited. Overall, Onechain Immunotherapeutics and …See details»

OneChain Immunotherapeutics SL (OneChain Immunotherapeutics …

First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with …See details»

OneChain - EU-Startups

OneChain is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop immunotherapies against hematological neoplasms using CAR-T …See details»

OneChain | Who we are

Onechain Immunotherapeutics is a clinical stage biotech company based in Barcelona (Spain) and focused in the development of CAR T therapies for the treatment of oncological diseases.See details»

NanoCell Therapeutics Inc. and OneChain Immunotherapeutics S.L …

May 16, 2024 NanoCell Therapeutics Inc. 150 N Radnor Chester Road Suite A210 Wayne PA 19087 United StatesSee details»

2024 – Nanocell Therapeutics

May 16, 2024 Wayne, PA – March 19, 2024 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing in-vivo cell engineering solutions based on its proprietary non-viral, DNA …See details»

OneChain | Whistleblowing Channel

Electronically: [email protected]. By mail to the following address: C/Baldiri Reixac, n.º 4-6, Edificio Torres R+D+I, Parc Científic de Barcelona, (08028) Barcelona – to the …See details»

Onechain - Crunchbase Company Profile & Funding

ONECHAIN is a global cryptocurrency exchange that provides Spot and Futures trading between Bitcoin (BTC), Ethereum (ETH), Tether (USDT), and other altcoins.See details»

May 2024 – Nanocell Therapeutics

May 16, 2024 NanoCell Therapeutics Inc. 150 N Radnor Chester Road Suite A210 Wayne PA 19087 United StatesSee details»

Pipeline - OneChain

T-ALL comprises 10–15% of all acute leukemias diagnosed in children and 20–25% in adults, with a median diagnostic age of 9 years. Survival of patients with T-ALL treated with intensive …See details»

linkstock.net © 2022. All rights reserved